Nearly 400 Drugs in Development for Infectious Diseases - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nearly 400 Drugs in Development for Infectious Diseases


Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections, are now in development with US biopharmaceutical research companies, according to a report from the Pharmaceutical Research and Manufacturers of America (PhRMA).

Infectious diseases were the leading cause of death in the United States until the 1920s. Vaccines and antimicrobials have proven to effectively treat and prevent many diseases and conditions, but infectious diseases and the emerging resistance of pathogens that cause disease still pose a very serious threat to patients, the report says.

The 394 medicines and vaccines in development for infectious diseases, all in human clinical trials or under review by the Food and Drug Administration (FDA), include 226 for viral infections, 124 for bacterial infections, 24 for fungal infections and 15 for parasitic infections. Examples include:

• A medicine for the most common and difficult-to-treat form of hepatitis C that inhibits the enzyme essential for viral replication.
• An anti-malarial drug that has shown activity against Plasmodium falciparum malaria that is resistant to current treatments.
• A potential new antibiotic to treat methicillin-resistant Staphylococcus aureus (MRSA).
• A novel treatment that works by blocking the ability of the smallpox virus to spread to other cells, thus preventing it from causing disease.

Source: Pharmaceutical Research and Manufacturers of America

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
31%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here